What were the key takeaways from MiNK Therapeutics's earnings call?

What factors drove the changes in MiNK Therapeutics's revenue and profit?

What guidance did MiNK Therapeutics's management provide for the next earnings period?

What is MiNK Therapeutics's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for MiNK Therapeutics year over year?

What does MiNK Therapeutics do and what are its main business segments?

What is MiNK Therapeutics's gross profit margin?

What is the market's earnings forecast for MiNK Therapeutics next quarter?

- **Clinical Milestones**: ARDS Phase II/III trial launching Q2 2026, with initial data expected H2 2026. GvHD trial dosing begins Q2 2026.
- **Financial Strength**: $13.4M cash, 40% opex reduction, $3M post-year-end funding. Non-dilutive capital secures 70%+ pipeline programs.
- **Innovation**: Off-the-shelf iNKT cells show durable survival in cancer (23+ months), 70% ARDS survival vs. 10% control. IL-15 combination trials under discussion.
- **Expansion Strategy**: C-Further pediatric oncology collaboration, NIH GvHD funding, and Ukraine ARDS partnership enable rapid global execution.

**【CEO Summary Section】**
- **Clinical Progress**: Phase II trials in solid tumors (e.g., gastric, lung) show median survival >23 months, complete remission >2 years in checkpoint-refractory cancers. ARDS trial demonstrates 70% survival vs. 10% control, with cytokine modulation and pathogen clearance.
- **Pipeline Expansion**: 
  - **GvHD Trial**: NIH/NIAID and Mary Gooze-funded Phase II at University of Wisconsin targeting hematopoietic stem cell transplant patients.
  - **ARDS Trial**: Randomized Phase II/III launching in Ukraine and U.S., testing off-the-shelf iNKT cells in hypoxemic pneumonia.
  - **PRAME Program**: C-Further consortium collaboration for pediatric oncology, with $1M+ non-dilutive funding.
- **Financial Efficiency**: 2025 cash balance increased to $13.4M (from $4.6M), operating expenses reduced 40%, with $3M raised post-year-end.
- **Strategic Funding**: Secured $1M+ in non-dilutive funding for IND-enabling studies, retaining double-digit commercial participation.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Net loss $2.6M ($0.56/share), full-year loss $12.5M ($2.93/share). Cash balance $13.4M, supporting 2026 milestones.
- **Capital Allocation**: Disciplined use of at-the-market facility, extending runway through 2026 for clinical trials.

**【Q&A Highlights】**
- **ARDS Trial Design**: Randomized Phase II comparing iNKT cells + standard care vs. standard care alone. Eligibility based on ARDS criteria, with focus on multidrug-resistant infections.
- **IPF Strategy**: Preclinical and human data show iNKT depletion in IPF. Trial design to be announced, leveraging non-dilutive funding.
- **IL-15 Collaboration**: No formal announcements; strategic discussions ongoing, but no disclosed trials with 797 or other assets.

MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript

- **Clinical Milestone**: agenT-797 achieves 23-month median OS in refractory solid tumors, exceeding historical benchmarks by 383%.
- **Strategic Expansion**: $15.5M+ cash runway through 2026, supporting global Phase II/III pulmonary trial and GvHD study.
- **Manufacturing Strength**: 1B cells/donor yield enables cost-efficient stockpiling, with 3-year shelf life for iNKT cells.
- **Partnership Power**: Federal grants and academic collaborations reduce capital intensity by 70%+ for late-stage programs.


**【CEO Summary Section】**
- Presented updated clinical data from the Phase I trial of agenT-797 at SITC 2025, showing median overall survival of 23 months in patients with relapsed/refractory solid tumors (vs. <6 months expected). Complete remission observed in metastatic testicular cancer, durable partial responses in gastric and renal cell carcinomas.
- Highlighted iNKT cell therapy's dual TCR-dependent and TCR-independent mechanisms, reprogramming tumor microenvironments to restore immune function without systemic toxicity.
- Announced strategic partnerships with University of Wisconsin for GvHD trial (funded by DoD STTR Grant) and global Phase II/III trial for acute pulmonary dysfunction, targeting ventilator-free days and 28-day mortality.
- Onboarded Dr. Terese Hammond as Head of Inflammatory Diseases and Dr. John Holcomb to Board, strengthening clinical leadership.

**【CFO Financial Commentary】**
- Q3 2025 cash balance: $14.3M (plus $1.2M raised post-quarter via ATM, extending runway to 2026).
- Net loss: $2.9M (vs. $1.8M in Q3 2024), driven by clinical trial expansion and manufacturing scale-up.
- Implemented ATM sales agreement to minimize dilution, accessing capital at 700%+ premium to prior price.

**【Q&A Key Highlights】**
- **Combo Cohort Expansion**: Planning Phase II trial in second-line gastric cancer and germ cell tumors, leveraging external funding to minimize cost.
- **Pulmonary Trial Launch**: First patient dosing expected Q1 2026, with endpoints of 28-day mortality and ventilator-free days.
- **Manufacturing Scale-Up**: Achieved 1B cells/donor (3-year stability), stockpiling material for upcoming trials. Exploring nondilutive financing for large-scale production.
- **GvHD Trial Funding**: University of Wisconsin grant covers patient enrollment and immune monitoring, minimizing capital impact.


MiNK Therapeutics, Inc. (INKT) Q3 2025 Earnings Call Transcript

- **Breakthrough Clinical Data**: agenT-797 achieves 2+ year remission in testicular cancer and 40% tumor shrinkage in gastric cancer, driving Phase II expansion.
- **Financial Strength**: $13M equity raise extends runway to mid-2026; Q2 cash burn down 30% YoY.
- **Strategic Expansion**: GvHD prophylaxis trial begins in 2025 with external funding; ARDS trial targets 3M global incidence with 80% survival rate in ECMO patients.
- **Pipeline Momentum**: CAR-iNKT program IND-ready; FAP-CAR prioritized for immune-mediated diseases with minimal capital impact.

**【CEO Summary Section】**
- **Clinical Milestones**: Published durable complete remission in metastatic testicular cancer (2+ years) and 40% tumor shrinkage in refractory gastric cancer, both treated with agenT-797. Phase II trial at Memorial Sloan Kettering for gastric cancer expected to report data by end-2025.
- **Operational Efficiency**: Q2 operating cash burn reduced 30% YoY; extended cash runway to mid-2026 through $13M equity raise and strategic funding partnerships.
- **Pipeline Expansion**: 
  - **GvHD Prophylaxis Trial**: Phase I trial to begin in 2025 with 20-25 patients evaluating 1B cells dose; funded externally with minimal capital impact.
  - **ARDS Program**: Planning randomized Phase II/III trial with external funding; 80% survival in ECMO patients vs 10-22% control.
  - **Engineered iNKTs**: CAR-iNKT (MiNK-215) IND-enabling studies underway; FAP-CAR iNKT program prioritized for immune-mediated diseases.

**【CFO Financial Commentary】**
- **Financial Position**: $1.7M cash balance as of Q2; $13M equity raise post-quarter extends runway to mid-2026.
- **Net Loss**: Q2 2025 net loss $4.2M ($1.06/sh) vs $2.7M ($0.73/sh) in Q2 2024; year-to-date loss $7M ($1.76/sh) vs $6.5M ($1.82/sh).
- **Cost Management**: Streamlined operations reduce burn rate; non-cash expenses offset clinical investment.

**【Q&A Key Highlights】**
- **GvHD Trial Design**: Phase I will evaluate safety, engraftment success, infection rates, and GvHD incidence at 2 dose levels (1B cells target). Preclinical data shows superior tolerability vs existing agents.
- **Gastric Cancer Updates**: Mature follow-up data expected by year-end; focus on survival benefit in immune-desert tumors.
- **FAP-CAR Program**: IND-enabling studies complete; seeking partners to accelerate development with minimal capital impact.
- **ARDS Registrational Path**: FDA guidance on 28-day mortality endpoint; trial to assess ventilator-free days, oxygenation, and secondary infection prevention.

MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript

- **Breakthrough Cancer Data**: Testicular cancer patient achieved complete remission 24 months after single dose, with iNKT cells persisting >6 months.
- **ARDS Innovation**: 70%+ survival in ventilated patients, positioning for accelerated FDA pathway.
- **Financial Efficiency**: Cash burn reduced 47% YoY, $3.2M runway supports strategic partnerships.
- **Government Endorsement**: NIAID funding for GvHD trial, aligning with FDA's novel immune therapy priorities.

**【CEO Clinical Progress & Strategic Momentum】**
- **Solid Tumor Pipeline**: Phase 2 gastric cancer trial with agenT-797 in combination with checkpoint inhibitors shows immune activation and early clinical responses in second-line patients. A Phase 1 testicular cancer patient achieved durable complete remission 24 months after a single infusion without lymphodepletion.
- **Immuno-Oncology Expansion**: New data in ARDS (acute respiratory distress syndrome) demonstrates 70%+ survival rates in ventilated patients, with plans for compassionate use programs and accelerated regulatory pathways.
- **Strategic Partnerships**: Engaging in 3 distinct proposals across oncology, immunology, and next-gen engineered cell therapies, with potential to diversify capital and accelerate development.
- **Government Support**: Secured probable funding from NIAID for GvHD (graft vs. host disease) program, with collaboration at University of Wisconsin.

**【CFO Financial Summary】**
- **Cash Position**: $3.2M as of Q1 2025, with operating cash burn reduced 47% YoY to $1.3M.
- **Net Loss**: $2.8M for Q1 2025 vs. $3.8M in Q1 2024, driven by operational efficiency improvements.

**【Q&A Highlights】**
- **Testicular Cancer Update**: Patient achieved CR 24 months post-infusion, with persistence of iNKT cells >6 months. Additional clinical sweeps planned for Phase 1 patients.
- **Gastric Cancer Timeline**: Targeting data readout by end-2025, with enrollment ongoing.
- **GvHD Trial Design**: Phase 1 evaluating both prophylactic and steroid-refractory acute GvHD, with potential for faster regulatory path in prophylaxis.
- **Funding Certainty**: NIAID award expected in June, with minimal capital outlay required for GvHD program.

MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript

- **Strategic Expansion**: Board addition of biodefense expert Dr. Kadlec and RNA tech partnership with Autonomous for next-gen cancer therapies.
- **Clinical Breakthroughs**: 80% survival in severe respiratory distress; Phase 2 gastric cancer data showing immune reactivation to be presented mid-2025.
- **New Indications**: GvHD trial with potential government funding; exploring iNKT in biodefense.
- **Financial Stability**: Reduced cash burn ($9.6M vs. $15.8M YoY) and $4.6M cash balance supporting 2025 operations.

**【CEO Summary Section】**
- **Strategic Leadership Updates**: Addition of Dr. Robert Kadlec to the Board for biodefense expertise; departure of General Counsel Bob Foster for government service.
- **Collaboration Expansion**: Partnership with Autonomous Therapeutics to integrate RNA payloads into iNKT cell therapies for metastatic cancer targeting.
- **Clinical Milestones**: 
  - Phase 2 study in refractory gastroesophageal cancer shows immune reactivation (e.g., interferon-gamma levels, T cell infiltration) when combining 797 with checkpoint inhibitors before chemotherapy.
  - AgenT-797 demonstrates 80% survival rate in severe respiratory distress patients on ECMO, preventing secondary infections.
  - PRAME-TCR iNKT program shows precision targeting of intracellular tumor antigens in solid tumors.
- **New Indications**: Planning Phase 1 trial for 797 in acute GvHD with potential NIAID funding; exploring biodefense applications.

**【CFO Financial Commentary】**
- **Financial Health**: Cash balance of $4.6 million; reduced cash usage ($9.6M vs. $15.8M YoY) reflecting cost containment.
- **Net Loss**: $10.8 million for 2024, down from $22.5 million prior year, driven by operational efficiency.

**【Q&A Highlights】**
- **Phase 2 Trial**: Majority of 40-patient enrollment complete; data expected mid-2025 at major conference.
- **Pipeline Advancement**: FAP-CAR-iNKT (IL-15 armored) IND filing planned for 2025; PRAME-TCR shows immune recruitment beyond conventional T cells.
- **Funding Strategy**: NIAID funding for GvHD trial pending; backup plans include external partnerships.
- **Cash Runway**: Sufficient funds for 2025 operations with focus on fiscal prudence.


Actual	-1.8	-2.3	-1.8	-1.9	-2.3	-1.7	-1.8	-1.5	-1.6	-1.1	-0.7	-0.5	-0.62	-0.7	-1.06	-0.65
Forecast	-4.1	-2.0667	-2.325	-2.26	-2.0973	-2.3795	-1.975	-1.8158	-1.525	-1.525	-0.9817	-0.8007	-0.4867	-0.6077	-0.5467	-0.855	-0.68
Surprise	+56.10%	-11.29%	+22.58%	+15.93%	-9.66%	+28.56%	+8.86%	+17.39%	-4.92%	+27.87%	+28.70%	+37.55%	-27.39%	-15.19%	-93.89%	+23.98%	0.00%

Actual	--	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	--
Forecast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

INKT

INKT fundamentals

INKT Q4 2025 Earnings Preview

Earnings Call

You can ask Aime

INKT

INKT fundamentals

INKT Q4 2025 Earnings Preview

Earnings Call

INKT Earnings Call Summary for Q4/20258:30 AM on Mar 31, 2026

INKT Earnings Call Summary for Q3/20258:30 AM on Nov 14, 2025

INKT Earnings Call Summary for Q2/20258:30 AM on Aug 14, 2025

INKT Earnings Call Summary for Q1/20258:30 AM on May 15, 2025

INKT Earnings Call Summary for Q4/20248:30 AM on Mar 18, 2025

You can ask Aime